HealthMore in Health→
EGFR x HER3 Antibody-Drug Conjugate Locks In Phase III Dose for Lung Cancer
Key Takeaways
- An investigational EGFR x HER3 antibody-drug conjugate, iza-bren, showed increasing clinical activity at higher dose levels in a randomized Phase I dose-expansion cohort.
- At the recommended Phase III dose of 2.5 mg/kg, the objective response rate was 33.3%, the confirmed objective response rate was 29.6%, and median progression-free survival was 6.9 months.
- All enrolled patients had previously progressed on a third-generation EGFR inhibitor, and nearly two-thirds had also received platinum-based chemotherapy.
- Mandatory primary G-CSF prophylaxis was linked to an improved hematologic safety profile versus earlier reported experience; no treatment-related deaths occurred and one patient discontinued for a treatment-related adverse event.
DE
DT Editorial Team··via medicalxpress.com